IRVING, Texas / Aug 01, 2024 / Business Wire / The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.71 per share of common stock, a 15% increase from $0.62 per share in the prior quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024.
“This marks our eighth consecutive annual dividend increase, underscoring the confidence in our business fundamentals and the strength of our balance sheet and free cash flow generation,” said Brian Tyler, chief executive officer. “We remain dedicated to our disciplined capital deployment strategy, prioritizing growth and creating value for our shareholders.”
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
| Last Trade: | US$603.32 |
| Daily Change: | 3.50 0.58 |
| Daily Volume: | 787,362 |
| Market Cap: | US$76.590B |
February 04, 2025 November 06, 2024 August 26, 2024 August 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
